Cardiovascular and antacid treatment and mortality in oxygen-dependent pulmonary fibrosis : A population-based longitudinal study
Ekström, Magnus LU
and Bornefalk-Hermansson, Anna
(2016)
In Respirology
21(4).
p.705-711
- Abstract
BACKGROUND AND OBJECTIVE: Severe idiopathic pulmonary fibrosis is associated with an increased risk of cardiovascular disease and gastro-oesophageal reflux, which may influence prognosis. We evaluated associations between cardiovascular and antacid medications, and mortality, in oxygen-dependent pulmonary fibrosis (PF) of unknown cause.
METHODS: Prospective population-based study of adults starting long-term oxygen therapy (LTOT) for PF in Sweden 2005-2009. PF of unknown cause was defined by excluding patients with known or probable secondary PF. Time-dependent associations between medications and all-cause mortality were analysed using extended Cox regression, adjusting for potential confounders including age, sex, vital... (More)
BACKGROUND AND OBJECTIVE: Severe idiopathic pulmonary fibrosis is associated with an increased risk of cardiovascular disease and gastro-oesophageal reflux, which may influence prognosis. We evaluated associations between cardiovascular and antacid medications, and mortality, in oxygen-dependent pulmonary fibrosis (PF) of unknown cause.
METHODS: Prospective population-based study of adults starting long-term oxygen therapy (LTOT) for PF in Sweden 2005-2009. PF of unknown cause was defined by excluding patients with known or probable secondary PF. Time-dependent associations between medications and all-cause mortality were analysed using extended Cox regression, adjusting for potential confounders including age, sex, vital capacity, blood gases, body mass index, performance status, comorbidity and concurrent medications.
RESULTS: Of 462 included patients, 329 (71%) died under observation. No patient was lost to follow-up. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB) were associated with reduced adjusted mortality (HR 0.63; 0.47-0.85) and antiplatelet drugs with increased mortality (HR 1.49; 1.11-2.00), largely driven by higher mortality in women. There were no associations with mortality for antacid treatments, β-blockers, diuretics or statins.
CONCLUSION: In oxygen-dependent PF, treatment with ACEI/ARB was associated with improved survival, antiplatelet drugs with decreased survival, whereas there was no association between antacid, β-blocker, diuretic or statin treatment and survival.
(Less)
- author
- Ekström, Magnus
LU
and Bornefalk-Hermansson, Anna
- organization
- publishing date
- 2016-05
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Cardiovascular Disease, clinical epidemiology
- in
- Respirology
- volume
- 21
- issue
- 4
- pages
- 6 pages
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:27009834
- scopus:84961828103
- wos:000374688900018
- ISSN
- 1440-1843
- DOI
- 10.1111/resp.12781
- language
- English
- LU publication?
- yes
- id
- 8477e8eb-c4cd-4be1-8060-1c8ff06a7baf
- date added to LUP
- 2016-04-11 13:36:50
- date last changed
- 2024-04-18 22:24:31
@article{8477e8eb-c4cd-4be1-8060-1c8ff06a7baf,
abstract = {{<p>BACKGROUND AND OBJECTIVE: Severe idiopathic pulmonary fibrosis is associated with an increased risk of cardiovascular disease and gastro-oesophageal reflux, which may influence prognosis. We evaluated associations between cardiovascular and antacid medications, and mortality, in oxygen-dependent pulmonary fibrosis (PF) of unknown cause.</p><p>METHODS: Prospective population-based study of adults starting long-term oxygen therapy (LTOT) for PF in Sweden 2005-2009. PF of unknown cause was defined by excluding patients with known or probable secondary PF. Time-dependent associations between medications and all-cause mortality were analysed using extended Cox regression, adjusting for potential confounders including age, sex, vital capacity, blood gases, body mass index, performance status, comorbidity and concurrent medications.</p><p>RESULTS: Of 462 included patients, 329 (71%) died under observation. No patient was lost to follow-up. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB) were associated with reduced adjusted mortality (HR 0.63; 0.47-0.85) and antiplatelet drugs with increased mortality (HR 1.49; 1.11-2.00), largely driven by higher mortality in women. There were no associations with mortality for antacid treatments, β-blockers, diuretics or statins.</p><p>CONCLUSION: In oxygen-dependent PF, treatment with ACEI/ARB was associated with improved survival, antiplatelet drugs with decreased survival, whereas there was no association between antacid, β-blocker, diuretic or statin treatment and survival.</p>}},
author = {{Ekström, Magnus and Bornefalk-Hermansson, Anna}},
issn = {{1440-1843}},
keywords = {{Cardiovascular Disease; clinical epidemiology}},
language = {{eng}},
number = {{4}},
pages = {{705--711}},
publisher = {{Wiley-Blackwell}},
series = {{Respirology}},
title = {{Cardiovascular and antacid treatment and mortality in oxygen-dependent pulmonary fibrosis : A population-based longitudinal study}},
url = {{http://dx.doi.org/10.1111/resp.12781}},
doi = {{10.1111/resp.12781}},
volume = {{21}},
year = {{2016}},
}